妊娠糖尿病市場規模、佔有率和成長分析：按診斷類型、治療類型、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球妊娠糖尿病市場價值為 92.1 億美元，預計到 2025 年將成長至 100.5 億美元，到 2033 年將成長至 201.6 億美元，在預測期（2026-2033 年）內複合年成長率為 9.1%。

全球妊娠糖尿病 (GDM) 市場正迅速發展，其主要促進因素是妊娠期葡萄糖耐受不良盛行率的不斷上升，這給母親和嬰兒都帶來了重大風險。肥胖、高齡產婦和人口結構變化等因素加劇了這一成長，導致高危險群增加。數位健康解決方案在這一市場擴張中發揮著至關重要的作用，它們能夠實現有效的數據共用，使醫療專業人員能夠快速調整胰島素治療方案並改善治療效果。雅培和德康等公司提供的妊娠期專用連續血糖監測技術創新正逐步納入醫保範圍，並促使醫院投資建設遠端醫療基礎設施。這個充滿活力的生態系統不僅拓展了收入來源，也推動了公共政策的轉變，將 GDM 管理納入常規產前護理。

全球妊娠糖尿病市場成長要素

孕婦對妊娠糖尿病的認知度不斷提高，顯著推動了對篩檢和管理方案的需求。隨著孕婦對妊娠糖尿病的了解日益加深，並積極參與產前護理，醫療服務提供者也積極回應，實施全面的檢測方案和個人化的治療計劃。這項轉變擴大了診斷設備、血糖監測系統和各種治療服務的市場。此外，患者參與度的提高也促進了遠端監測等數位健康平台的使用。這正在建立一個更廣泛的生態系統，不僅能夠改善患者的治療效果和滿意度，還能確保妊娠期糖尿病市場的持續成長和永續性。

全球妊娠糖尿病市場的限制因素

全球妊娠糖尿病市場成長受到保險報銷政策限制的限制。醫療保險公司通常將與妊娠糖尿病相關的醫療設備和服務歸類為「非必需」或「可選」。這種分類為醫療服務提供者帶來不確定性，可能導致他們優先選擇可全額報銷的傳統低成本替代方案，從而延緩先進監測技術的應用。這種猶豫不決抑制了對創新解決方案的需求，並阻礙了對新產品研發的投資。因此，製造商在拓展分銷網路方面面臨障礙，被迫推遲新產品上市，直到資金籌措來源更加明確，最終阻礙了市場擴張。此外，患者的自付費用可能會降低其對建議治療方案的依從性，進一步影響整體市場滲透率。

妊娠糖尿病的全球市場趨勢

隨著個人化營養策略引入患者管理，全球妊娠糖尿病市場正在發生顯著變化。醫療專業人員擴大利用持續血糖監測數據來製定個人化飲食計劃，根據每位患者獨特的代謝反應最佳化宏量營養素組成和用餐時間。這種轉變有助於改善血糖控制，並支持胎兒健康發育。營養技術平台的進步可提供即時回饋和預測性見解，從而提高患者參與度和對飲食療法的依從性。因此，以營養為中心的策略正成為醫療服務提供者提供全面、以結果為導向且符合孕產婦健康目標的照護的關鍵差異化優勢。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球妊娠糖尿病市場規模：依診斷類型分類

• 口服葡萄糖耐受試驗（OGTT）
• 空腹血糖測試
• 隨機血糖檢測
• 糖化血紅素（HbA1c）檢測

全球妊娠糖尿病市場規模：依治療類型分類

• 飲食療法和生活方式調整
• 胰島素治療
• 口服藥物
• 持續血糖監測（CGM）
• 體育活動計劃

全球妊娠糖尿病市場規模：依最終用戶分類

• 醫院
• 診斷檢查室
• 居家照護環境
• 婦產科診所

全球妊娠糖尿病市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球妊娠糖尿病市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi SA
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Becton Dickinson and Company
• Medtronic PLC
• Dexcom, Inc.
• Ascensia Diabetes Care Holdings AG
• Merck & Co., Inc.
• AstraZeneca PLC
• Boehringer Ingelheim GmbH
• Baxter International Inc.
• OmniPod（Insulet Corporation）
• B. Braun Melsungen AG
• Tandem Diabetes Care, Inc.
• Global Diabetes Supply
• Edgepark Medical Supplies
• National Diabetes Supplies

結論與建議

Global Gestational Diabetes Market size was valued at USD 9.21 Billion in 2024 and is poised to grow from USD 10.05 Billion in 2025 to USD 20.16 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).

The global gestational diabetes mellitus (GDM) market is rapidly evolving, driven by the rising prevalence of glucose intolerance during pregnancy which poses significant risks to both mothers and infants. This accelerating growth is influenced by factors such as obesity, delayed childbearing, and changing demographic trends, increasing the number of at-risk individuals. Digital health solutions play a crucial role in this market expansion, enabling effective data sharing that allows healthcare providers to adjust insulin therapies swiftly and improve health outcomes. Innovations in continuous glucose monitoring tailored for pregnancy from companies like Abbott and Dexcom are attracting insurance reimbursement, prompting hospitals to invest in telehealth infrastructure. This dynamic ecosystem not only enhances revenue avenues but also fosters shifts in public policy to integrate GDM management into routine prenatal care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gestational Diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gestational Diabetes Market Segments Analysis

Global gestational diabetes market is segmented by diagnosis type, treatment type, end user, distribution channel and region. Based on diagnosis type, the market is segmented into Oral Glucose Tolerance Test (OGTT), Fasting Blood Sugar Test, Random Blood Sugar Test and Hemoglobin A1c (HbA1c) Test. Based on treatment type, the market is segmented into Dietary Changes & Lifestyle Modification, Insulin Therapy, Oral Medications, Continuous Glucose Monitoring (CGM) and Physical Activity Programs. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Homecare Settings and Maternity Clinics. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gestational Diabetes Market

The rising awareness among expectant mothers regarding gestational diabetes is significantly boosting the demand for screening and management solutions. As mothers-to-be become more informed and proactive in their prenatal care, healthcare providers are adapting by introducing comprehensive testing protocols and tailored treatment plans. This evolution enhances the market for diagnostic devices, glucose monitoring systems, and various therapeutic services. Additionally, increased engagement from patients promotes the use of digital health platforms that enable remote monitoring. This creates a more extensive ecosystem that not only improves patient outcomes and satisfaction but also ensures sustained growth and sustainability within the gestational diabetes market.

Restraints in the Global Gestational Diabetes Market

The growth of the global gestational diabetes market is hindered by restrictive reimbursement policies, as healthcare payers frequently categorize devices and services related to this condition as non-essential or elective. This classification creates uncertainty for providers, who may be reluctant to adopt advanced monitoring technologies in favor of traditional, lower-cost alternatives that are fully reimbursed. Such hesitance dampens demand for innovative solutions and hampers investment in new product development. As a result, manufacturers face obstacles in scaling their distribution efforts and may postpone launching new offerings until clearer funding options arise, ultimately stifling market expansion. Additionally, out-of-pocket expenses incurred by patients can limit adherence to recommended treatments, which further impacts overall market uptake.

Market Trends of the Global Gestational Diabetes Market

The Global Gestational Diabetes market is evolving significantly with the integration of personalized nutrition strategies in patient management. Healthcare providers are increasingly utilizing continuous glucose monitoring data to develop individualized dietary plans, allowing for tailored macronutrient compositions and meal timing based on each patient's unique metabolic response. This shift enhances glycemic control and supports healthy fetal development. As nutrition technology platforms advance, they provide real-time feedback and predictive insights that encourage patient engagement and adherence to dietary regimens. Consequently, nutrition-focused strategies are becoming essential differentiators for providers delivering comprehensive, outcomes-oriented care aligned with maternal health objectives.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Gestational Diabetes Market Size by Diagnosis Type & CAGR (2026-2033)

• Market Overview
• Oral Glucose Tolerance Test (OGTT)
• Fasting Blood Sugar Test
• Random Blood Sugar Test
• Hemoglobin A1c (HbA1c) Test

Global Gestational Diabetes Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Dietary Changes & Lifestyle Modification
• Insulin Therapy
• Oral Medications
• Continuous Glucose Monitoring (CGM)
• Physical Activity Programs

Global Gestational Diabetes Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Homecare Settings
• Maternity Clinics

Global Gestational Diabetes Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gestational Diabetes Market Size & CAGR (2026-2033)

• North America (Diagnosis Type, Treatment Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Diagnosis Type, Treatment Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis Type, Treatment Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis Type, Treatment Type, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis Type, Treatment Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascensia Diabetes Care Holdings AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OmniPod (Insulet Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tandem Diabetes Care, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Diabetes Supply
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Edgepark Medical Supplies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• National Diabetes Supplies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations